Structure–activity relationships of 2-aryl-1H-indole inhibitors of the NorA efflux pump in Staphylococcus aureus

Joseph I. Ambrus [a], Michael J. Kelso [a], John B. Bremner [a,*], Anthony R. Ball [b], Gabriele Casadei [b], Kim Lewis [b]

[a] School of Chemistry, University of Wollongong, Wollongong, NSW 2522, Australia
[b] Department of Biology and Antimicrobial Discovery Center, Northeastern University, Boston, MA 02115, USA

ABSTRACT

The synthesis of 22 2-aryl-1H-indoles, including 12 new compounds, has been achieved via Pd- or Rh-mediated methodologies, or selective electrophilic substitution. All three methods were based on elaborations from simple indole precursors. SAR studies on these indoles and 2-phenyl-1H-indole in Staphylococcus aureus as NorA efflux pump inhibitors indicated 5-nitro-2-(3-methoxycarbonyl)phenyl-1H-indole was a slightly more potent inhibitor than the lead INF55. A promising new antibacterial lead compound against S. aureus (2-phenyl-1H-indol-5-yl)-methanol, was also found.

© 2008 Elsevier Ltd. All rights reserved.

Efflux pumps compromise the efficacy of a wide range of antibiotics by actively extruding them from bacterial cells.[1,2] The pumps can be expressed in many different forms in both Gram-positive[3] and Gram-negative bacteria,[4] and for some species a variety of pumps may be present with different or overlapping substrates. For the important community and nosocomially acquired human pathogen Staphylococcus aureus a number of pumps have been identified, including NorA, which has been shown to play a role in the development of clinical multidrug resistance (MDR) by this organism.[5] One promising strategy for combating MDR in S. aureus is to treat infections with a combination of a NorA efflux pump inhibitor and a conventional antibiotic, with the pump inhibitor serving to restore the antibiotic's potency by reducing its efflux from bacterial cells.[6]

Reported classes of NorA inhibitors include flavones and flavonolignans,[7] pyrroloquinoxalines,[8] 4-arylpyridine-3,5-dicarboxylate esters,[9] N-aryl ureas,[10] and indoles.[11]

From the indole class, 5-nitro-2-phenylindole (2, INF55) (Scheme 1) represents a promising lead structure capable of producing a 4-fold increase in S. aureus susceptibility to ciprofloxacin when co-administered with the antibiotic at a concentration of 1.5 µg/mL.[11]

Structure–activity relationships for INF55 are only just starting to emerge. In one theoretical COMFA (3D-QSAR) analysis, it was suggested that replacement of the indole 5-nitro group with other electron-withdrawing substituents should be favorable for activity.[10] A series of 2-arylbenzo[b]thiophenes related to INF55 were

* Corresponding author. Tel.: +61 2 42214255; fax +61 2 42214287.
E-mail address: john_bremner@uow.edu.au (J.B. Bremner).

Method	Compound	R	
a	2	NO$_2$	(INF55)
b	3	SO$_3$H	
c	4	SO$_2$NH$_2$	
d	5	SO$_2$OCH$_3$	
e	6	SO$_2$On-Pr	

Scheme 1. Reagents and conditions: (a) NaNO$_3$, H$_2$SO$_4$ (concd), −20 °C; [17] (b) i—ClSO$_3$H, 0 °C to rt, 30 min; ii—NaOH, H$_2$O, rt and then 1 M HCl; (c) (i) followed by (ii) NH$_3$/THF, rt; (d) (i) followed by (ii) MeOH, pyridine, rt; (e) (i) followed by (ii) n-PrOH, pyridine rt.

recently reported as NorA inhibitors[12] suggesting that the indole-NH is not essential for activity. In 2006, we reported preliminary structure–activity data showing that various substituents around the 2-aryl ring of INF55 improved NorA inhibitory potency.[13] For example, 5'-benzyloxy-2'-hydroxymethyl-5-nitroindole was found to potentiate the activity of the mild antibacterial agent berberine (a known substrate of NorA) more than 15-fold against the NorA overexpressing S. aureus strain K2361 at a concentration of 0.8 µg/mL (cf. INF55 potentiates berberine activity to the same degree at the higher concentration of 3.0 µg/mL).

The current work discloses our latest systematic SAR exploration around the 2-aryl ring of INF55 and details the first experimental description of the effects of substituting the indole 5-nitro group. The goal of this study was to obtain a deeper understanding of the SAR of INF55 and analogs with a view to increasing potency against NorA in *S. aureus*. Furthermore, we sought to broaden our knowledge of substituent tolerance around the INF55 nucleus in order to advance our long-term goals of developing potent dual-action antimicrobials,[14] including both non-cleavable hybrid molecules[15] and cleavable "mutual" prodrugs[16] which combine antibacterial agents and NorA-inhibiting moieties into single molecules.

INF55 **2** was synthesized in one step (Scheme 1) from commercially available 2-phenylindole **1** using the known regioselective nitration procedure.[17] Compounds **3–6** were each synthesized in two steps starting from **1** and proceeding via a 5-chlorosulfonyl-2-phenylindole intermediate **1a** (Scheme 2). The intermediate was cleanly accessed using a previously unreported, highly regioselective 5-chlorosulfonation of 2-phenylindole. Briefly, **1** was stirred with neat chlorosulfonic acid at 0 °C and allowed to warm to rt with stirring over 30 min. The reaction mixture was then poured slowly onto crushed ice and the product filtered, washed with water, and dried under vacuum (80%). As **1a** degraded when left at rt over a period of several days, the freshly prepared crude 5-chlorosulfonyl-2-phenylindole (**1a**) was then reacted with appropriate nucleophiles to furnish the 5-sulfonyl-2-phenylindole derivatives **3–6** (Scheme 1) in good yields (**3** = 72%, **4** = 70%, **5** = 57%, **6** = 76%).

We propose that the regioselective 5-chlorosulfonation of 2-phenylindole proceeds via the electrophilic aromatic substitution mechanism shown in Scheme 2. Under strongly acidic conditions (e.g., neat ClSO$_3$H) indoles are known to protonate at the indole C3 position which serves to protect this normally reactive site from electrophiles. C3 protonation of 2-phenylindole would yield a 2-phenylindolinium cation that could potentially react directly with a weak nucleophile like ClSO$_3^-$ to form an indoline-2-chlorosulfonate adduct.

A related indoline-2-sulfonate adduct has been reported as a participant in the regioselective formation of 5-substituted indoles.[18] What is perhaps more likely is that the indoline-2-chlorosulfonate is formed in a concerted process that proceeds via the cyclic 6-membered transition state shown in Scheme 2. The resulting indoline-2-chlorosulfonate, which contains an *ortho*-substituted aniline ring, should direct a ClSO$_2^+$ electrophile to the indole C5 position (i.e., *para* to the aniline nitrogen), with indole **1a** returned after quenching with water.

Compounds **14**, **15**, **18**, and **22** were prepared by direct C2 arylation of commercially available indoles **7–9** with the respective aryl iodides **10–13** using the recently reported Rh-catalyzed coupling procedure (Scheme 3).[19] Yields for the couplings were disap-

Compound	R^1		Compound	R^2	R^3
7	CN		**10**	H	H
8	CO$_2$Me		**11**	H	H
9	H		**12**	CO$_2$Me	H
			13	H	CO$_2$Me

Compound/Method	R^1	R^2	R^3
14	CN	H	H
15	CO$_2$Me	H	H
16	CO$_2$H	H	H
17	CH$_2$OH	H	H
18	H	CO$_2$Me	H
19	H	CH$_2$OH	H
20	NO$_2$	CO$_2$Me	H
21	NO$_2$	CH$_2$OH	H
22	H	H	CO$_2$Me
23	H	H	CH$_2$OH
24	NO$_2$	H	CO$_2$Me
25	NO$_2$	H	CH$_2$OH

Scheme 3. Reagents and conditions: (a) [Rh(coe)$_2$Cl]$_2$, [p-CF$_3$-C$_6$H$_4$]$_3$P, Cs(OPiv)$_2$, 1,4-dioxane, 120 °C;[19] (b) 1 M LiOH, THF, 75 °C; (c) LiAlH$_4$, THF, rt; (d) LiBH$_4$, THF, rt; (e) NaNO$_3$, H$_2$SO$_4$ (concd), −20 °C.[17]

pointing (14–43%) but nevertheless provided sufficient quantities of pure materials for use in our study. 2D NOESY spectra of compounds **18** and **22** confirmed that indole C2 arylation had occurred in preference to arylation at C3 (i.e., NOEs were observed between the indole H3 and H4 signals for both **18** and **22**).

The methyl ester **15** was smoothly hydrolyzed to the carboxylic acid **16** under standard conditions using LiOH/THF, and **15** was also reduced without incident to the hydroxymethyl derivative **17** using LiAlH$_4$ (Scheme 3). Esters **18** and **22** were reduced in essentially quantitative yield to their respective hydroxylmethyl derivatives **19** and **23** using LiBH$_4$. The same esters **18** and **22** could be regioselectively nitrated at −20 °C in NaNO$_3$/H$_2$SO$_4$ mixtures[17] to provide the 5-nitro-2-arylindole derivatives **20** and **24** in 80% and 81%, yields respectively. Compounds **22** and **24** were comprehensively characterized by 2D NMR spectroscopy, with NOESY spectra confirming that mononitration had occurred selectively at the indole C5 position for both compounds (i.e., observed NOEs included NH/H7, H6/H7, and H3/H4). Esters **20** and **24** were subsequently reduced to their respective hydroxymethyl derivatives **23** and **25** in high yields (90% and 79%, respectively) using LiBH$_4$ (Scheme 3).

A Pd-mediated intramolecular cyclization approach was used to access the 2′-substituted-2-arylindoles **31-35**. All attempts to access these analogs via Rh-catalyzed 2-arylation of indoles with *ortho*-substituted aryl iodides failed. *N*-benzoylindoles **26** and **27**

Scheme 2. Proposed mechanism for the regioselective 5-chlorosulfonation of 2-phenylindole in neat chlorosulfonic acid.

**Scheme 4.** Reagents and conditions: (a) Pd(OAc)$_2$, AcOH, 110 °C;[20] (b) tBuOK, tBuOH/H$_2$O, 82 °C;[20] (c) AcCl, MeOH, reflux; (d) LiAlH$_4$, THF, rt; (e) BH$_3$-THF, rt.[13] *Compounds synthesized previously.[13]

(Scheme 4) were converted to their respective 6-oxo-6H-isoindolo[2,1-a]indoles **28** and **29** using the palladium (II) acetate promoted oxidative intramolecular cyclization procedure reported by Itahara.[20] Ring-opening of compounds **28** and **29** by lactam hydrolysis (t-BuOK, t-BuOH, H$_2$O)[20] yielded the 2′-carboxylic acids **30**[20] and **31**,[13] respectively. Compound **30** was converted to the methyl ester **32** under standard conditions (AcCl/MeOH) and to the hydroxymethyl derivative **33** using LiAlH$_4$. The acid 2-(2′-carboxyphenyl)-5-nitroindole **31** was converted to its methyl ester **34** using AcCl/MeOH and to its hydroxymethyl derivative **35**[13] using BH$_3$.THF.

The potentiation activities of compounds **1**–**6** and **14**–**17** (Table 1) were determined against the wild type S. aureus strain (8325-4), a mutant strain deleted in NorA (K1758) and a NorA overexpressing strain (K2378) with the antibacterial agent berberine using a checkerboard assay which involved co-administration of varying concentrations of the inhibitor and berberine.[21]

This assay provides access to combinatorial interactions (synergistic, antagonistic, indifferent, or additive) between the two mol-

Table 1
Bacterial inhibition and potentiation results for C5-substituted analogs of INF55 (**2**) with berberine in S. aureus

		MIC (μM) of inhibitor		
Compound	R	Δ norA K1758 plus berberine	WT 8325-4 plus berberine	NorA++ K2378 plus berberine
1	H	NP	65 (4)	259.0 (4)
2	NO$_2$	NP	3.3 (2)	6.5 (2)
3	SO$_3$H	NP	NP	NP
4	SO$_2$NH$_2$	NP	NP	NP
5	SO$_2$OCH$_3$	IA	IA	IA
6	SO$_2$On-Pr	IA	IA	IA
14	CN	NP	3.6 (2)	7.1 (2)
15	CO$_2$Me	NP	NP	NP
16	CO$_2$H	NP	NP	NP
17	CH$_2$OH	IA	IA	IA

NP denotes no antibacterial potentiation; IA denotes intrinsic antibacterial activity. Potentiation values are shown in brackets and are the ratios of berberine MICs with and without inhibitor present.

Table 2
Bacterial inhibition and potentiation results for 2-aryl analogs of INF55 (**2**) with berberine in S. aureus

			MIC (μM) of inhibitor		
Compound	R^1	R^2	Δ norA K1758 plus berberine	WT 8325-4 plus berberine	NorA++ K2378 plus berberine
32	H	2′-CO$_2$Me	NP	20	20
33	H	2′-CH$_2$OH	NP	45	45
18	H	3′-CO$_2$Me	40	5	10
19	H	3′-CH$_2$OH	NP	45	45
22	H	4′-CO$_2$Me	NP	20	40
23	H	4′-CH$_2$OH	NP	22	45
2[25]	NO$_2$	H	0.63	1.3	1.3
34	NO$_2$	2′-CO$_2$Me	NP	34	NP
35[13]	NO$_2$	2′-CH$_2$OH	24	47	47
20	NO$_2$	3′-CO$_2$Me	0.51	1.0	1.0
21	NO$_2$	3′-CH$_2$OH	9	5	9
24	NO$_2$	4′-CO$_2$Me	NP	17	NP
25	NO$_2$	4′-CH$_2$OH	5	2	2

NP denotes no antibacterial potentiation. The inhibitor concentrations are the minimum for potentiation of berberine MIC by factors of 3.3 (K1758), 3.3 (8325-4), and 13.3 (K2378).

ecules. The inhibitor 'MIC' is defined as the lowest concentration of inhibitor required to potentiate berberine's MIC by at least a factor of two. The MIC values for berberine (as the chloride salt) alone against S. aureus were 269 μM (8325-4) and 67 μM (K1758)), and 2152 μM (K2378). The activities of compounds **18**–**25** and **32**–**35** (Table 2) were determined against the same three strains of S. aureus but using our previously published methodology[13] (even though not as complete as the full checkerboard assay), in order to enable a better comparison with the prior results on compounds with other 2-aryl substituents. Briefly, for this methodology, cells were grown in the presence of a sub-inhibitory concentration of berberine [81 μM (8325-4), 20 μM (K1758), and 161 μM (K2378)] and varying concentrations of the test compounds. Bacterial growth was monitored by measuring the absorption at 600 nm and MIC values were determined. MICs represent the minimum concentrations of the test compounds (in combination with the fixed concentration of berberine) that completely inhibited cell growth during an 18 h incubation at 37 °C. Differences in the values for INF55 (**2**) in Tables 1 and 2 reflect the difference in the potentiation assay used, although the different result with the NorA knockout mutant K1758 (Table 1) was not resolved.

The inherent antibacterial activity of each compound in the absence of berberine was >1000 μM (the testing limit employed in this assay), except for the sulfonate esters **5** and **6** (MIC values of 174 and 79.3 μM, respectively, against all three S. aureus strains), and **17**. The alcohol **17** showed an MIC of 14.0 μM against the NorA knockout strain, and 28.0 μM against both the wild type and NorA overexpressing strains.[22] Interestingly, in further testing, **17** was shown to be inactive as an antibacterial against a panel of other Gram-negative and Gram-positive pathogens.[23]

Compounds **1**–**6** and **14**–**17** (Table 1) varied only with respect to substituents at the indole-C5 position allowing for direct conclusions to be drawn regarding the importance of the 5-NO$_2$ group of INF55. Three of the compounds tested (**5**, **6**, and **17**) showed intrinsic antibacterial activity, and thus the potentiation of the MIC value could not be accurately determined for these analogs.

Structure–activity conclusions regarding the importance of the C5 position of INF55 for inhibitory activity against the NorA pump include:

(1) Removing the C5 substituent (**1**) is deleterious to activity.

(2) Carbonyl based electron-withdrawing groups at C5 (**15** and **16**) abolish all activity.

(3) Inhibitors with sulfonic acids/esters/amides at C5 (compounds **3**–**6**) show no potentiation. Compounds **5** and **6** display mild intrinsic antibacterial activity.

(4) Substitution with a nitrile group leads to retention of potency with **14** showing similar potentiation activity to INF55.

Compounds **20**, **21**, **24**, **25**, **34**, and **35** (Table 2)[24] systematically explore the effects of methyl ester and hydroxymethyl substituents at the 2′, 3′, and 4′ positions of the 2-aryl ring of INF55. Compounds **18**, **19**, **22**, **23**, **32**, and **33** explore these same effects in compounds lacking the 5-NO$_2$ of INF55. One of the goals of this study was to identify analogs of INF55 that retained or improved NorA inhibitory potency while containing functional groups useful for covalent attachment to antimicrobial agents. We were particularly interested in analogs bearing hydroxymethyl groups since these could be incorporated into dual-action NorA inhibitor-antibacterial 'mutual' prodrugs bearing labile ester linkages. Success of this strategy of course requires that the alcohol-bearing INF55 analog released from such prodrugs is a potent NorA inhibitor. The methyl ester analogs were intermediates in the synthesis of the hydroxymethyl analogs and were tested here to add depth to the SAR. The analogous series lacking the 5-NO$_2$ group was explored in an attempt to identify inhibitors which might avoid the known toxicity problems of nitroaromatic compounds.

Table 2 shows that all compounds lacking 5-NO$_2$ groups (i.e., **18**, **19**, **22**, **23**, **32**, and **33**) were significantly less potent than INF55. Another trend to emerge was that, apart from **24** with respect to **25**, each of the methyl ester analogs was more potent than its corresponding hydroxymethyl derivative. The 3′-CO$_2$Me derivative **20** proved to be the most active compound identified in this study, displaying slightly higher potency than INF55 against all three *S. aureus* strains. Another important finding was that analog **25** bearing a 4′-CH$_2$OH group was almost equipotent with INF55 against the wild type and NorA overexpressing strain. This suggests that **25** is the best compound to progress into our studies of mutual prodrugs employing labile ester linkages. It should be mentioned that there is a possibility that non-covalent complex formation between berberine and the indole-based inhibitors reported here may play a role in the potentiation observed.[26]

In conclusion, the SAR data for indole-based NorA efflux pump inhibitors have been deepened by this study and three new potent inhibitors, **14**, **20**, and **25**, have been uncovered. Inhibitor **25** represents a promising candidate for incorporation into dual action mutual prodrugs targeting the NorA pump. In addition, a new indole derivative **17** was identified with specific antibacterial activity against *S. aureus*. The mode of action of this compound and the reason for its selective activity against this organism remains to be investigated.

Acknowledgments

References and notes

1. Marquez, B. *Biochimie* **2005**, *87*, 1137.
2. Lomovskaya, O.; Zgurskaya, H. I.; Totrov, M.; Watkins, W. J. *Nat. Rev. Drug Discov.* **2007**, *6*, 56.
3. Kaatz, G. W. In *Frontiers in Antimicrobial Resistance*; White, D. G., Alekshun, M. N., McDermott, P. F., Eds.; ASM Press: Washington, DC, 2005; p 275.
4. Poole, K. *Clin. Microbiol. Infect.* **2004**, *10*, 12.
5. Kaatz, G. W.; Seo, S. M.; Ruble, C. A. *Antimicrob. Agents Chemother.* **1993**, *37*, 1086.
6. Bremner, J. B. *Pure Appl. Chem.* **2007**, *79*, 2143.
7. Guz, N. R.; Stermitz, F. R.; Johnson, J. B.; Beeson, T. D.; Willen, S.; Hsiang, J.-F.; Lewis, K. *J. Med. Chem.* **2001**, *44*, 261.
8. Vidaillac, C.; Guillon, J.; Moreau, S.; Arpin, C.; Lagardere, A.; Larrouture, S.; Dallemagne, P.; Caignard, D.-H.; Quentin, C.; Jarry, C. *J. Enzyme Inhib. Med. Chem.* **2007**, *22*, 620.
9. Marquez, B.; Neuville, L.; Moreau, N. J.; Genet, J.-P.; dos Santos, A. F.; Cano de Andrade, M. C.; Goulart Sant'Ana, A. E. *Phytochemistry* **2005**, *66*, 804.
10. Markham, P. N.; Mulhearn, D. C.; Neyfakh, A. A.; Crich, D.; Jaber, M.-R.; Johnson, M. E.; Influx, Inc., USA. Application: WO, 2000, 32196, 119 pp.
11. Markham, P. N.; Westhaus, E.; Klyachko, K.; Johnson, M. E.; Neyfakh, A. A. *Antimicrob. Agents Chemother.* **1999**, *43*, 2404.
12. Fournier dit Chabert, J.; Marquez, B.; Neville, L.; Joucla, L.; Broussous, S.; Bouhours, P.; David, E.; Pellet-Rostaing, S.; Marquet, B.; Moreau, N.; Lemaire, M. *Bioorg. Med. Chem.* **2007**, *15*, 4482.
13. Samosorn, S.; Bremner, J. B.; Ball, A.; Lewis, K. *Bioorg. Med. Chem.* **2006**, *14*, 857.
14. Bremner, J. B.; Ambrus, J. I.; Samosorn, S. *Curr. Med. Chem.* **2007**, *14*, 1459.
15. Ball, A. R.; Casadei, G.; Samosorn, S.; Bremner, J. B.; Ausubel, F. M.; Moy, T. I.; Lewis, K. *ACS Chem. Biol.* **2006**, *1*, 594.
16. Singh, G.; Dev Sharma, P. *Indian J. Pharm. Sci.* **1994**, *56*, 69.
17. Noland, W. E.; Rush, K. R.; Smith, L. R. *J. Org. Chem.* **1966**, *31*, 65.
18. Russell, H. F.; Harris, B. J.; Hood, D. B.; Thompson, E. G.; Watkins, A. D.; Williams, R. D. *Org. Prep. Proced. Int.* **1985**, *17*, 391.
19. Wang, X.; Lane, B. S.; Sames, D. *J. Am. Chem. Soc.* **2005**, *127*, 4996.
20. Itahara, T. *Bull. Chem. Soc. Jpn.* **1981**, *54*, 305.
21. A checkerboard assay was conducted to specify the degree of potentiation of berberine by the test compounds and to determine the specificity of these compounds for the NorA efflux pump. Serial 2-fold dilutions of berberine and a test compound were mixed in each well of a 96-well microtiter plate so that each row (and column) contained a fixed amount of one agent and increasing amounts of the second agent. The resulting plate presents a pattern in which every well contains a unique combination of concentrations between the two molecules. The concentrations of berberine ranged from 100 to 12.5 µg/mL (*S. aureus* 8325-4) and 200 to 800 µg/mL (*S. aureus* K2378), while inhibitor concentrations ranged from 1.56 to 100 µg/mL. Each plate also contained a row and column in which a serial dilution of each agent was present alone. Cells were added to each well at a final concentration of 5×10^5 CFU/mL, and plates incubated at 37 °C for 20 h. Growth was assayed by absorption at 600 nm with a microtiter plate reader (Spectramax PLUS384, Molecular Devices). An OD less than 0.05 was considered to reveal no growth.
22. For the antimicrobial susceptibility assay, cells (10^5 CFU/mL) were inoculated into broth and dispensed at 0.2 mL/well in 96-well microtiter plates. MICs were determined by serial 2-fold dilution of the test compound. The MIC was defined as the concentration of an antimicrobial that completely inhibited cell growth during an 18–20 h incubation at 37 °C. Growth was assayed with a microtiter plate reader (Spectramax PLUS384; Molecular Devices) by monitoring absorption at 600 nm.
23. Compound **17** was tested against the following panel of Gram-negative pathogens with MICs given in brackets in µg/mL; the highest concentration tested was 200 µg/mL: *Escherichia coli* O157:H7, BW25113, and UT189 (all >200); *Salmonella typhimurium* CS132 (>200); *Pseudomonas aeruginosa* PA01 and PA14 (both > 200). This compound was also tested against a number of Gram-positive pathogens as follows with MICs in brackets in µg/mL; the highest concentration tested was 200 µg/mL for all species apart from the *Clostridium* species, where the highest concentration tested was 100 µg/mL: *Enterococcus faecalis* MMH594, V583, and OG1RF (all >200); *Clostridium difficile* VPI10463, CD196, and CD2001 (all>100), and *Clostridium perfringens* (>100).
24. Biological testing of compounds **30** and **31** was not undertaken as the latter compound with an *ortho*-carboxylic acid group had been tested previously[13] and showed poor potentiation of berberine, while the former compound was only made as a precursor for the corresponding methyl ester **32** in order to obtain a complete set of methyl esters for SAR purposes.
25. The MIC of this compound with berberine was also determined, for comparison purposes, against *S. aureus* K2361 and found to be 1.56 µg/mL, broadly commensurate with the previously obtained value (3 µg/mL)[13] in this NorA pump overexpressing strain.
26. Zloh, M.; Gibbons, S. *Theor. Chem. Acc.* **2007**, *117*, 231.